Cell line name |
MDA-MB-231 NAT1 down |
Synonyms |
NAT1 shRNA Clone 3; NAT1 Knockdown |
Accession |
CVCL_A9BB |
Resource Identification Initiative |
To cite this cell line use: MDA-MB-231 NAT1 down (RRID:CVCL_A9BB) |
Comments |
Group: Triple negative breast cancer (TNBC) cell line. Population: Caucasian. Characteristics: Transfected with a pcDNA5/FRT derived construct with a NATb promoter driving the expression of NAT1 (NATb/NAT1*4). Doubling time: 27.2 hours (PubMed=29315819). Knockout cell: Method=shRNA knockdown; HGNC; 7645; NAT1. Transfected with: HGNC; 7645; NAT1. Transfected with: UniProtKB; P00557; Escherichia coli hygromycin-B 4-O-kinase (hph) (HygR). Derived from site: Metastatic; Pleural effusion; UBERON=UBERON_0000175. |
Sequence variations |
- Gene deletion; HGNC; 1787; CDKN2A; Zygosity=Homozygous (from parent cell line).
- Gene deletion; HGNC; 1788; CDKN2B; Zygosity=Homozygous (from parent cell line).
- Mutation; HGNC; 1097; BRAF; Simple; p.Gly464Val (c.1391G>T); ClinVar=VCV000040364; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6407; KRAS; Simple; p.Gly13Asp (c.38G>A); ClinVar=VCV000012580; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11730; TERT; Simple; c.1-124C>T (c.228C>T) (C228T); Zygosity=Unspecified; Note=In promoter (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Arg280Lys (c.839G>A); ClinVar=VCV000376657; Zygosity=Homozygous (from parent cell line).
|
Disease |
Breast adenocarcinoma (NCIt: C5214) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_0062 (MDA-MB-231) |
Sex of cell |
Female |
Age at sampling |
51Y |
Category |
Cancer cell line |
Publications | PubMed=29315819; DOI=10.1002/mc.22779 Stepp M.W., Doll M.A., Carlisle S.M., States J.C., Hein D.W. Genetic and small molecule inhibition of arylamine N-acetyltransferase 1 reduces anchorage-independent growth in human breast cancer cell line MDA-MB-231. Mol. Carcinog. 57:549-558(2018) PubMed=29964355; DOI=10.1002/mc.22869 Carlisle S.M., Trainor P.J., Doll M.A., Stepp M.W., Klinge C.M., Hein D.W. Knockout of human arylamine N-acetyltransferase 1 (NAT1) in MDA-MB-231 breast cancer cells leads to increased reserve capacity, maximum mitochondrial capacity, and glycolytic reserve capacity. Mol. Carcinog. 57:1458-1466(2018) PubMed=32555504; DOI=10.1038/s41598-020-66863-4 Carlisle S.M., Trainor P.J., Hong K.U., Doll M.A., Hein D.W. CRISPR/Cas9 knockout of human arylamine N-acetyltransferase 1 in MDA-MB-231 breast cancer cells suggests a role in cellular metabolism. Sci. Rep. 10:9804-9804(2020) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_A9BB
|
Encyclopedic resources |
Wikidata; Q108820869
|
Entry history |
Entry creation | 23-Sep-2021 |
Last entry update | 05-Oct-2023 |
Version number | 7 |
---|